Overview

Avalere Cell & Gene Policy 360 is your go-to source for anticipating the impact policy and market developments will have on innovative therapies. Understand how to monitor the environment, hone your strategy, and assess business impact.

Attributes

This monthly update provides in-depth analysis from Avalere experts on developments specific to cell and gene therapies (CGTs) and broader policies with implications for CGTs, including FDA guidance, coverage and reimbursement decisions, drug pricing proposals, and innovative contracting flexibilities.

Advantages

Stay informed of changes and their potential impact in order to support business planning, assess market opportunities, and identify early engagement opportunities.

Membership Benefits

Access to easy-to-navigate content with a summary description and “Avalere’s Take” on the most significant cell and gene policy developments.

Learn More

Megan West (Olsen)

Principal

Producing monthly updates and targeted insights on developments that affect cell and gene therapies, Megan West and a multidisciplinary team keep you informed by monitoring policy and regulatory changes with strategic business impacts.

Cell & Gene Policy 360 highlights guidance from the FDA, coding and reimbursement developments in the inpatient and outpatient settings of care, regulatory flexibilities for value-based arrangements, drug pricing proposals, and other timely developments.